Dysbiosis‐induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice

Peng Chen, Peter Stärkel, Jerrold R. Turner, Samuel B. Ho, Bernd Schnabl – 24 September 2014 – Intestinal barrier dysfunction is an important contributor to alcoholic liver disease (ALD). Translocated microbial products trigger an inflammatory response in the liver and contribute to steatohepatitis. Our aim was to investigate mechanisms of barrier disruption after chronic alcohol feeding. A Lieber‐DeCarli model was used to induce intestinal dysbiosis, increased intestinal permeability, and liver disease in mice.

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Paola Dongiovanni, Salvatore Petta, Cristina Maglio, Anna Ludovica Fracanzani, Rosaria Pipitone, Enrico Mozzi, Benedetta Maria Motta, Dorota Kaminska, Raffaela Rametta, Stefania Grimaudo, Serena Pelusi, Tiziana Montalcini, Anna Alisi, Marco Maggioni, Vesa Kärjä, Jan Borén, Pirjo Käkelä, Vito Di Marco, Chao Xing, Valerio Nobili, Bruno Dallapiccola, Antonio Craxi, Jussi Pihlajamäki, Silvia Fargion, Lars Sjöström, Lena M. Carlsson, Stefano Romeo, Luca Valenti – 24 September 2014

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

Tariq Ahmad, Philip Yin, Jeffrey Saffitz, Paul J. Pockros, Jacob Lalezari, Mitchell Shiffman, Bradley Freilich, Joann Zamparo, Kyle Brown, Dessislava Dimitrova, Monica Kumar, Doug Manion, Margo Heath‐Chiozzi, Robert Wolf, Eric Hughes, Andrew J. Muir, Adrian F. Hernandez – 24 September 2014 – Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)‐based therapy to direct‐acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity.

Subscribe to